1. Home
  2. HRMY vs CMPR Comparison

HRMY vs CMPR Comparison

Compare HRMY & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$38.87

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Cimpress plc (Ireland)

CMPR

Cimpress plc (Ireland)

N/A

Current Price

$74.44

Market Cap

1.6B

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
CMPR
Founded
2017
1994
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Publishing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.6B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HRMY
CMPR
Price
$38.87
$74.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
2
Target Price
$51.33
$80.50
AVG Volume (30 Days)
802.8K
177.1K
Earning Date
11-04-2025
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
50.44
N/A
EPS
3.17
1.37
Revenue
$825,944,000.00
$3,461,387,000.00
Revenue This Year
$23.11
$8.23
Revenue Next Year
$16.15
$4.83
P/E Ratio
$12.26
$54.33
Revenue Growth
21.13
3.65
52 Week Low
$25.52
$35.21
52 Week High
$40.93
$81.11

Technical Indicators

Market Signals
Indicator
HRMY
CMPR
Relative Strength Index (RSI) 66.02 61.52
Support Level $38.12 $73.60
Resistance Level $40.87 $76.20
Average True Range (ATR) 1.25 2.67
MACD -0.07 0.26
Stochastic Oscillator 65.10 80.29

Price Performance

Historical Comparison
HRMY
CMPR

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About CMPR Cimpress plc (Ireland)

Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.

Share on Social Networks: